ABSTRACT
Objectives Antiepileptic and antiarrhythmic drugs inhibit voltage-gated sodium (Na+) channels (VGSCs), and preclinical studies show that these medications reduce tumour growth, invasion and metastasis. We investigated the association between VGSC inhibitor use and survival in breast, bowel and prostate cancer patients.
Design Retrospective cohort study.
Setting Individual electronic primary healthcare records extracted from the Clinical Practice Research Datalink (CPRD).
Participants Records for 132,996 patients with a diagnosis of breast, bowel or prostate cancer.
Primary and secondary outcome measures Adjusted Cox proportional hazards regression was used to analyse cancer-specific survival associated with exposure to VGSC inhibitors. Exposure to non-VGSC-inhibiting antiepileptic medication and other non-VGSC blockers were also considered. Drug exposure was treated as a time-varying covariate to account for immortal time bias.
Results During 1,002,225 person-years of follow-up, there were 42,037 cancer-specific deaths. 53,724 (40.4%) cancer patients had at least one prescription for a VGSC inhibitor of interest. Increased risk of cancer-specific mortality was associated with exposure to this group of drugs (HR 1.59, 95% CI 1.56-1.63, p<0.001). This applied to VGSC-inhibiting tricyclic antidepressants (HR 1.61, 95% CI 1.50-1.65, p<0.001), local anaesthetics (HR 1.49, 95% CI 1.43-1.55, p<0.001) and anticonvulsants (HR 1.40, 95% CI 1.34-1.48, p<0.001), and persisted in sensitivity analyses. In contrast, exposure to VGSC-inhibiting Class 1c and 1d antiarrhythmics was associated with significantly improved cancer-specific survival (HR 0.75, 95% CI 0.64-0.88, p<0.001 and HR 0.54, 95% CI 0.33-0.88, p=0.01, respectively).
Conclusions Association between VGSC inhibitor use and mortality in cancer patients varies according to indication. Exposure to VGSC-inhibiting antiarrhythmics, but not anticonvulsants, supports findings from preclinical data, with improved survival. However, additional confounding factors may underlie these associations, highlighting the need for further study.
Strengths and limitations of this study
Primary care research data with large sample size and statistical power.
No direct information on metastasis as an outcome.
Drug exposure data are based on prescriptions.
Drug exposure is treated as a time-varying covariate to account for immortal time bias.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bmjopen.bmj.com/content/6/9/e011661.long
Funding Statement
This work was supported by the Medical Research Council (G1000508) and Wellcome Trust through the Centre for Future Health at the University of York.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed following ethics approval from the Department of Biology Ethics Committee, University of York (WB201909).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Abstract updated to include quantitative measures and clarify data source.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
